Background Glecaprevir and pibrentasvir are direct-acting antiviral agents with pangenotypic
activity and a high barrier to resistance. We evaluated the efficacy and safety of 8-week …

Background & Aims Hepatitis C virus (HCV) therapy that is highly efficacious, pangenotypic,
with a high barrier to resistance and short treatment duration is desirable. The efficacy and …

Although direct‐acting antiviral (DAA) therapies for chronic hepatitis C virus (HCV) infection
have demonstrated high rates of sustained virologic response, virologic failure may still occur…

Nonalcoholic fatty liver disease (NAFLD) is a prevalent and complex disease that confers a
high risk of severe liver disorders. Despite such public and clinical health importance, very …

Background ABT-494 is a potent and selective Janus kinase (JAK) 1 inhibitor being developed
for the treatment of several autoimmune disorders, with potential for an improved safety …

Background & Aims The combination of ABT-493 (NS3/4A protease inhibitor) plus ABT-530 (NS5A
inhibitor) has shown high rates of sustained virologic response at post-treatment …

Aims Upadacitinib (ABT‐494) is a selective Janus kinase 1 inhibitor being developed for
treatment of auto‐immune inflammatory disorders. This work evaluated effects of high‐fat meal, …

Radiological reports are a rich source of clinical data which can be mined to assist with
biosurveillance of emerging infectious diseases. In addition to biosurveillance, radiological …

Background: Injection drug use is the primary mode of transmission for hepatitis C virus (HCV),
and treatment guidelines recommend treating HCV-infected people who use drugs; …

Background Glecaprevir–pibrentasvir results in high rates of sustained virological response
in patients with chronic hepatitis C virus (HCV) genotype 1–6 infection. Data for glecaprevir–…